Cutaneous and Systemic Leishmaniasis Market
Cutaneous and Systemic Leishmaniasis Market Study by Pentavalent Antimonials, Antifungal Drugs, and Anti-Leishmanial/Antimicrobial Drugs from 2024 to 2034
Analysis of Cutaneous and Systemic Leishmaniasis Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Cutaneous and Systemic Leishmaniasis Market Outlook (2024 to 2034)
The global cutaneous and systemic leishmaniasis market is projected to increase from a valuation of US$ 368.6 million in 2024 to US$ 487.5 million by the end of 2034. The market has been evaluated to expand at a CAGR of 2.8% from 2024 to 2034.
Cutaneous and systemic leishmaniasis are caused by the Leishmania genus of protozoan parasites. This condition primarily affects the skin, but it can extend to other body areas. Cutaneous and systemic leishmaniasis is a major health concern, especially in developing countries. Early diagnosis, suitable treatment, and public health initiatives are paramount to stopping its spread.
- According to the Pan American Health Organization in 2021, 51 countries reported nearly 222,000 new autochthonous cases to the World Health Organization Of the nine countries in the world with a significant number of cases of cutaneous leishmaniasis, three are in America, Brazil, Colombia, and Peru.
Due to such prevailing cases, the advancing treatments for leishmaniasis are expected to become more popular.
- Only around 200,000 new cases of cutaneous leishmaniasis are reported to the World Health Organization (WHO) each year, out of an estimated 600,000 to 1 million new cases worldwide. Roughly 95% of instances of cutaneous leishmaniasis take place in particular areas. Approximately 80% of the cases of cutaneous leishmaniasis recorded globally come from this region, including sections of North America, Central America, and South America and areas surrounding the Mediterranean Sea.
Cutaneous leishmaniasis is becoming more well-known to the public and medical professionals, which is increasing the number of cases diagnosed and people receiving treatment. Furthermore, it is anticipated that creating novel, more potent therapies for cutaneous leishmaniasis would propel market expansion.
Notwithstanding the promising future, demand for treatment solutions is hampered by issues such as the high cost of diagnostics, a dearth of treatment alternatives, and low awareness. Greater government financing can help spread the spread of this disease to a great extent. The use of advanced treatment methodologies, combination therapy development, and early diagnosis are contributing to cutaneous and systemic leishmaniasis market growth.
Novel non-pharmacological methods are also becoming more and more popular. The application of intense cold to afflicted regions, known as cryotherapy, has demonstrated potential in the treatment of leishmaniasis lesions. Similarly, patients looking for non-invasive treatments have an option with local heat therapy, which is usually administered at 40 °C to 42 °C. Patients and professionals alike now have even more targeted therapy choices because of the introduction of topical paromomycin formulations.
The management of leishmaniasis as a whole has benefited from the evolution of prevention techniques. Nowadays, doctors understand how critical it is to address underlying issues that might worsen a patient's condition or reduce the effectiveness of treatment, such as malnutrition and recurring systemic or local infections. This all-encompassing strategy for prevention is expected to be extremely important in lowering the frequency and severity of leishmaniasis cases.
| Report Attribute | Detail |
|---|---|
| Cutaneous and Systemic Leishmaniasis Market Size (2024E) | US$ 368.6 Million |
| Forecasted Market Value (2034F) | US$ 487.5 Million |
| Global Market Growth Rate (2024 to 2034) | 2.8% CAGR |
| Canada Market Growth Rate (2024 to 2034) | 3.7% CAGR |
| China Market Value (2034F) | US$ 38 Million |
| North America Market Share (2024E) | 50.7% |
| East Asia Market Share (2034F) | 18.1% |
| Key Companies Profiled | Gilead Sciences, Inc.; Profounda Pharmaceuticals; Knight Therapeutics Inc.; Janssen Global Services, LLC; Albert David Ltd.; Jubilant Life Sciences Ltd.; Novartis AG; Sanofi; Endo Pharmaceuticals Inc.; Bristol-Myers Squibb Company; United Biotech Pvt. Ltd. |
Don't Need a Global Report?
save 40%! on Country & Region specific reports
What are the Factors Pushing Adoption of Cutaneous and Systemic Leishmaniasis Treatments?
“Significant Investments by Companies in Research Endeavors”
Among several cutaneous and systemic trial groups treated with pharmaceuticals, a combination of multiple cutaneous and systemic leishmaniasis therapies has led to a higher proportion of efficacy. Complete cures for both cutaneous and systemic leishmaniasis have also been achieved with certain combinations. As a result, this element is contributing to the expansion of the cutaneous and systemic leishmaniasis market size.
Several companies operating in the markets are making significant investments in research endeavors aimed at creating innovative treatment options. In addition, several medications and treatments for both systemic and cutaneous leishmaniasis are presently undergoing clinical testing, with nearly all trial results anticipated to be favorable. These efforts are projected to open up new avenues for the management of systemic and cutaneous leishmaniasis.
“Increasingly Favorable Reimbursement Policies across Regions”
The global healthcare infrastructure is attracting investments from governments. In addition, several private health insurance companies offer a variety of reimbursement schedules for the easy and effective management of systemic and cutaneous leishmaniasis. People can now choose the type of reimbursement policy that best suits their needs and is likely to yield the most benefits.
What is a Major Challenge for Treatment Providers?
“Potential Risk of Side Effects Coupled with High Cost of Treatment”
Medications for cutaneous and systemic leishmaniasis are expensive. In addition, the medications taken for the treatment may have detrimental side effects. Development of new therapy approaches, however, is in progress and is expected to provide effective therapeutic measures against these diseases in addition to minimizing adverse effects.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Country-wise Evaluation
The market is substantial in countries such as the United States, Canada, Japan, China, and South Korea. Fact.MR states that the United States is set to hold a substantial cutaneous and systemic leishmaniasis market share in North America.
Why is the United States a Lucrative Market in This Space?
“Increased Adoption of Thermotherapy and Photodynamic Therapy”
| Attribute | United States |
|---|---|
| Market Value (2024E) | US$ 162 Million |
| Growth Rate (2024 to 2034) | 3.3% CAGR |
| Projected Value (2034F) | US$ 223 Million |
Applying regulated, targeted heat to skin lesions, thermotherapy is becoming increasingly popular due to its efficaciousness and patient-centered methodology. Concurrently, photodynamic therapy targets the parasites by mixing photosensitizing drugs with particular light wavelengths. While still in the experimental stage, this approach shows encouraging outcomes.
In the United States, these cutting-edge methods provide patients with alternatives to conventional drugs, minimizing side effects and enhancing adherence to therapy. This is a major substantial cutaneous and systemic leishmaniasis market trend. The country's patients and healthcare professionals are becoming more aware of these cutting-edge possibilities, which is driving up demand for leishmaniasis treatments. This is transforming the market and spurring more research and development in this area.
How is the Market for Cutaneous and Systemic Leishmaniasis Shaping Up in China?
“Health Insurance Schemes Reducing Leishmaniasis Treatment Costs”
| Attribute | China |
|---|---|
| Market Value (2024E) | US$ 27 Million |
| Growth Rate (2024 to 2034) | 3.7% CAGR |
| Projected Value (2034F) | US$ 38 Million |
National health insurance schemes are increasing the public's access to treatments in China. Government insurance policies that cover leishmaniasis treatments are significantly lowering the amount of money patients must pay out of pocket. This is boosting the demand for anti-leishmanial medications in China. For neglected tropical diseases like leishmaniasis, where cost can be a major obstacle to treatment, accessibility is especially crucial.
Category-wise Evaluation
The market is mainly divided into drug class, route of administration, indication type, and distribution channel. Drug class examines various drugs available for treatment and which drug holds a prominent share of the market, while the route of administration determines which route is significantly chosen for the treatments.
Which Drug Class is Preferred for Improved Patient Outcomes?
“Anti-microbial/Anti-leishmanial Agents Treating Diverse Range of Infections”
| Attribute | Anti-microbial/Anti-leishmanial |
|---|---|
| Segment Value (2024E) | US$ 299.3 Million |
| Growth Rate (2024 to 2034) | 3% CAGR |
| Projected Value (2034F) | US$ 401.7 Million |
Antimicrobial agents are essential for treating a wide range of infections. They are an essential part of contemporary medicine because of their capacity to both stop and even eradicate the growth of bacteria. They are widely employed in a variety of clinical and non-clinical contexts, from daily household products to hospitals.
Similarly, anti-leishmanial medications have grown in significance in the management of leishmaniasis, an illness brought on by parasites belonging to the Leishmania species. Particularly in areas where the disease is endemic, these medications are essential for managing the disease's transmission as well as its treatment.
Which Indication Type Accounts for Substantial Market Share?
“Cutaneous Leishmaniasis Holds Leading Market Share among All Indications”
| Attribute | Cutaneous Leishmaniasis |
|---|---|
| Segment Value (2024E) | US$ 277.6 Million |
| Growth Rate (2024 to 2034) | 2.7% CAGR |
| Projected Value (2034F) | US$ 363.4 Million |
Among other indicators, rising demand for treatment for cutaneous leishmaniasis is being driven by the disease's rising prevalence, particularly in developing countries. Need for efficient therapies for cutaneous leishmaniasis is growing since the World Health Organization reports around 200,000 new cases annually.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Business Competition
The market is competitive, with a few big players holding a dominant position. To satisfy product demand, key players in the cutaneous and systemic leishmaniasis market are adopting innovative strategies such as successful technology and distribution partnerships, investments in research for the creation of treatments and product launches, and an emphasis on adapting to evolving market trends such as developing treatment methodologies for cutaneous fibrosis and cutaneous mastocytosis.
Fact.MR provides detailed information about the price points of key cutaneous and systemic leishmaniasis treatment providers positioned across the world, sales growth, production capacity, and speculative technological expansion in this updated cutaneous and systemic leishmaniasis market report.
Key Segments of Cutaneous and Systemic Leishmaniasis Market Research
-
By Drug Class :
- Pentavalent Antimonials
- Antifungal Drugs
- Anti-leishmanial/Antimicrobial Drugs
-
By Route of Administration :
- Oral
- Injectable
- Topical
-
By Indication :
- Cutaneous Leishmaniasis
- Mucosal Leishmaniasis
- Visceral Leishmaniasis
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
-
By Region :
- North America
- Latin America
- Eastern Europe
- Western Europe
- East Asia
- South Asia & Pacific
- Middle East & Africa
Table of Content
- 1. Executive Summary
- 2. Industry Introduction, including Taxonomy and Market Definition
- 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments
- 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections
- 5. Pricing Analysis
- 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034
- 6.1. Drug Class
- 6.2. Route of Administration
- 6.3. Indication
- 6.4. Distribution Channel
- 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Drug Class
- 7.1. Pentavalent Antimonials
- 7.2. Antifungal Drugs
- 7.3. Anti-leishmanial/Antimicrobial Drugs
- 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Route of Administration
- 8.1. Oral
- 8.2. Injectable
- 8.3. Topical
- 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Indication
- 9.1. Cutaneous Leishmaniasis
- 9.2. Mucosal Leishmaniasis
- 9.3. Visceral Leishmaniasis
- 10. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Distribution Channel
- 10.1. Hospital Pharmacies
- 10.2. Retail Pharmacies
- 10.3. Drug Stores
- 10.4. Online Pharmacies
- 11. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, by Region
- 11.1. North America
- 11.2. Latin America
- 11.3. Western Europe
- 11.4. Eastern Europe
- 11.5. East Asia
- 11.6. South Asia & Pacific
- 11.7. Middle East & Africa
- 12. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 13. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 14. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 16. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 17. South Asia & Pacific Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 18. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries
- 19. Sales Forecast 2024 to 2034 by Drug Class, Route of Administration, Indication, Distribution Channel, and Region for 30 Countries
- 20. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard
- 21. Company Profile
- 21.1. Gilead Sciences, Inc.
- 21.2. Profounda Pharmaceuticals
- 21.3. Knight Therapeutics Inc.
- 21.4. Janssen Global Services, LLC
- 21.5. Albert David Ltd.
- 21.6. Jubilant Life Sciences Ltd.
- 21.7. Novartis AG
- 21.8. Sanofi
- 21.9. Endo Pharmaceuticals Inc.
- 21.10. Bristol-Myers Squibb Company
- 21.11. United Biotech Pvt. Ltd.
- 22. Assumptions and Acronyms Used
- 23. Research Methodology
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Global Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 02: Global Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 03: Global Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 04: Global Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 05: Global Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 06: Global Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 07: Global Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 08: Global Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 09: Global Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 10: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 11: Global Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 12: Global Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 13: Global Market Value (US$ Mn) Analysis, by Region, 2019 to 2023
Table 14: Global Market Value (US$ Mn) Analysis, by Region, 2024 to 2034
Table 15: Global Market Value (US$ Mn) Opportunity Analysis, by Region, 2024 to 2034
Table 16: North America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 17: North America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 18: North America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 19: North America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 20: North America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 21: North America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 22: North America Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 23: North America Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 24: North America Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 25: North America Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 26: North America Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 27: North America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 28: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 29: North America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 30: North America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 31: Latin America Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 32: Latin America Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 33: Latin America Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 34: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 35: Latin America Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 36: Latin America Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 37: Latin America Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 38: Latin America Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 39: Latin America Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 40: Latin America Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 41: Latin America Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 42: Latin America Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 43: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 44: Latin America Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 45: Latin America Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 46: Western Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 47: Western Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 48: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 49: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 50: Western Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 51: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 52: Western Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 53: Western Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 54: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 55: Western Europe Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 56: Western Europe Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 57: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 58: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 59: Western Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 60: Western Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 61: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 62: Eastern Europe Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 63: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 64: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 65: Eastern Europe Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 66: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 67: Eastern Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 68: Eastern Europe Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 69: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 70: Eastern Europe Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 71: Eastern Europe Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 72: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 73: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 74: Eastern Europe Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 75: Eastern Europe Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 76: East Asia Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 77: East Asia Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 78: East Asia Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 79: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 80: East Asia Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 81: East Asia Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 82: East Asia Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 83: East Asia Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 84: East Asia Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 85: East Asia Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 86: East Asia Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 87: East Asia Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 88: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 89: East Asia Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 90: East Asia Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 91: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 92: South Asia & Pacific Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 93: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 94: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 95: South Asia & Pacific Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 96: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 97: South Asia & Pacific Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 98: South Asia & Pacific Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 99: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 100: South Asia & Pacific Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 101: South Asia & Pacific Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 102: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 103: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 104: South Asia & Pacific Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 105: South Asia & Pacific Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
Table 106: MEA Market Value (US$ Mn) Analysis, by Country, 2019 to 2023
Table 107: MEA Market Value (US$ Mn) Analysis, by Country, 2024 to 2034
Table 108: MEA Market Value (US$ Mn) Opportunity Analysis, by Country, 2024 to 2034
Table 109: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2019 to 2023
Table 110: MEA Market Value (US$ Mn) Analysis, by Drug Class, 2024 to 2034
Table 111: MEA Market Value (US$ Mn) Opportunity Analysis, by Drug Class, 2024 to 2034
Table 112: MEA Market Value (US$ Mn) Analysis, by Route of Administration, 2019 to 2023
Table 113: MEA Market Value (US$ Mn) Analysis, by Route of Administration, 2024 to 2034
Table 114: MEA Market Value (US$ Mn) Opportunity Analysis, by Route of Administration, 2024 to 2034
Table 115: MEA Market Value (US$ Mn) Analysis, by Indication, 2019 to 2023
Table 116: MEA Market Value (US$ Mn) Analysis, by Indication, 2024 to 2034
Table 117: MEA Market Value (US$ Mn) Opportunity Analysis, by Indication, 2024 to 2034
Table 118: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2019 to 2023
Table 119: MEA Market Value (US$ Mn) Analysis, by Distribution Channel, 2024 to 2034
Table 120: MEA Market Value (US$ Mn) Opportunity Analysis, by Distribution Channel, 2024 to 2034
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Global Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 02: Global Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 03: Global Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 04: Global Market Incremental $ Opportunity, 2024 to 2034
Figure 05: Global Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 06: Global Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 07: Global Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 08: Global Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 09: Global Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 10: Global Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 11: Global Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 12: Global Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 13: Global Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 14: Global Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 15: Global Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 16: Global Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 17: Global Market Share and BPS Analysis by Region, 2024 & 2034
Figure 18: Global Market Y-o-Y Growth Projections by Region, 2024 to 2034
Figure 19: Global Market Attractiveness Analysis by Region, 2024 to 2034
Figure 20: North America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 21: North America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 22: North America Market Value Y-o-Y Growth and Forecast, 2034
Figure 23: North America Market Incremental $ Opportunity, 2024 to 2034
Figure 24: North America Market Share Analysis by Country, 2024 & 2034
Figure 25: North America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 26: North America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 27: North America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 28: North America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 29: North America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 30: North America Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 31: North America Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 32: North America Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 33: North America Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 34: North America Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 35: North America Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 36: North America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 37: North America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 38: North America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 39: Latin America Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 40: Latin America Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 41: Latin America Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 42: Latin America Market Incremental $ Opportunity, 2024 to 2034
Figure 43: Latin America Market Share Analysis by Country, 2024 & 2034
Figure 44: Latin America Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 45: Latin America Market Attractiveness Analysis by Country, 2024 to 2034
Figure 46: Latin America Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 47: Latin America Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 48: Latin America Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 49: Latin America Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 50: Latin America Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 51: Latin America Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 52: Latin America Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 53: Latin America Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 54: Latin America Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 55: Latin America Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 56: Latin America Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 57: Latin America Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 58: Western Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 59: Western Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 60: Western Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 61: Western Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 62: Western Europe Market Share Analysis by Country, 2024 & 2034
Figure 63: Western Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 64: Western Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 65: Western Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 66: Western Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 67: Western Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 68: Western Europe Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 69: Western Europe Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 70: Western Europe Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 71: Western Europe Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 72: Western Europe Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 73: Western Europe Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 74: Western Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 75: Western Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 76: Western Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 77: Eastern Europe Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 78: Eastern Europe Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 79: Eastern Europe Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 80: Eastern Europe Market Incremental $ Opportunity, 2024 to 2034
Figure 81: Eastern Europe Market Share Analysis by Country, 2024 & 2034
Figure 82: Eastern Europe Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 83: Eastern Europe Market Attractiveness Analysis by Country, 2024 to 2034
Figure 84: Eastern Europe Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 85: Eastern Europe Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 86: Eastern Europe Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 87: Eastern Europe Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 88: Eastern Europe Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 89: Eastern Europe Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 90: Eastern Europe Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 91: Eastern Europe Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 92: Eastern Europe Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 93: Eastern Europe Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 94: Eastern Europe Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 95: Eastern Europe Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 96: East Asia Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 97: East Asia Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 98: East Asia Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 99: East Asia Market Incremental $ Opportunity, 2024 to 2034
Figure 100: East Asia Market Share Analysis by Country, 2024 & 2034
Figure 101: East Asia Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 102: East Asia Market Attractiveness Analysis by Country, 2024 to 2034
Figure 103: East Asia Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 104: East Asia Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 105: East Asia Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 106: East Asia Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 107: East Asia Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 108: East Asia Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 109: East Asia Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 110: East Asia Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 111: East Asia Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 112: East Asia Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 113: East Asia Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 114: East Asia Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 115: South Asia & Pacific Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 116: South Asia & Pacific Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 117: South Asia & Pacific Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 118: South Asia & Pacific Market Incremental $ Opportunity, 2024 to 2034
Figure 119: South Asia & Pacific Market Share Analysis by Country, 2024 & 2034
Figure 120: South Asia & Pacific Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 121: South Asia & Pacific Market Attractiveness Analysis by Country, 2024 to 2034
Figure 122: South Asia & Pacific Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 123: South Asia & Pacific Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 124: South Asia & Pacific Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 125: South Asia & Pacific Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 126: South Asia & Pacific Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 127: South Asia & Pacific Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 128: South Asia & Pacific Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 129: South Asia & Pacific Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 130: South Asia & Pacific Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 131: South Asia & Pacific Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 132: South Asia & Pacific Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 133: South Asia & Pacific Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Figure 134: MEA Market Value (US$ Mn) Historical Analysis, 2019 to 2023
Figure 135: MEA Market Value (US$ Mn) Forecast and Analysis, 2024 to 2034
Figure 136: MEA Market Value Y-o-Y Growth and Forecast, 2019 to 2034
Figure 137: MEA Market Incremental $ Opportunity, 2024 to 2034
Figure 138: MEA Market Share Analysis by Country, 2024 & 2034
Figure 139: MEA Market Y-o-Y Growth Projection by Country, 2024 to 2034
Figure 140: MEA Market Attractiveness Analysis by Country, 2024 to 2034
Figure 141: MEA Market Share and BPS Analysis by Drug Class, 2024 & 2034
Figure 142: MEA Market Y-o-Y Growth Projections by Drug Class, 2024 to 2034
Figure 143: MEA Market Attractiveness Analysis by Drug Class, 2024 to 2034
Figure 144: MEA Market Share and BPS Analysis by Route of Administration, 2024 & 2034
Figure 145: MEA Market Y-o-Y Growth Projections by Route of Administration, 2024 to 2034
Figure 146: MEA Market Attractiveness Analysis by Route of Administration, 2024 to 2034
Figure 147: MEA Market Share and BPS Analysis by Indication, 2024 & 2034
Figure 148: MEA Market Y-o-Y Growth Projections by Indication, 2024 to 2034
Figure 149: MEA Market Attractiveness Analysis by Indication, 2024 to 2034
Figure 150: MEA Market Share and BPS Analysis by Distribution Channel, 2024 & 2034
Figure 151: MEA Market Y-o-Y Growth Projections by Distribution Channel, 2024 to 2034
Figure 152: MEA Market Attractiveness Analysis by Distribution Channel, 2024 to 2034
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
How big is the cutaneous and systemic leishmaniasis market in 2024?
The global market for cutaneous and systemic leishmaniasis is estimated at US$ 368.6 million in 2024.
What is the projected demand growth for cutaneous and systemic leishmaniasis treatment?
Revenue from cutaneous and systemic leishmaniasis treatment is forecasted to reach US$ 487.5 million by 2034.
At what rate is the global market projected to expand?
The global market is projected to expand at a CAGR of 2.8% from 2024 to 2034.
How much share of global market revenue is North America evaluated to hold?
North America is forecasted to hold 53% share of the global market by 2034.
At what CAGR is the market projected to increase in Japan?
The market in Japan is projected to increase at 2.7% CAGR from 2024 to 2034.
What is the contribution of antifungal drugs to global market revenue?
Antifungal drugs are projected to account for 18.6% share of global market revenue by 2024.
Who are the prominent players in this market?
Some of the leading market players are Gilead Sciences, Inc., Profounda Pharmaceuticals, and Knight Therapeutics Inc.
Cutaneous and Systemic Leishmaniasis Market